Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) Operating Expenses: 2012-2024

Historic Operating Expenses for BioLineRx (BLRX) over the last 13 years, with Dec 2024 value amounting to -$15.5 million.

  • BioLineRx's Operating Expenses rose 34.22% to -$2.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$12.9 million, marking a year-over-year increase of 25.40%. This contributed to the annual value of -$15.5 million for FY2024, which is 17.84% up from last year.
  • Latest data reveals that BioLineRx reported Operating Expenses of -$15.5 million as of FY2024, which was up 17.84% from -$18.8 million recorded in FY2023.
  • BioLineRx's 5-year Operating Expenses high stood at -$15.5 million for FY2024, and its period low was -$23.8 million during FY2021.
  • Moreover, its 3-year median value for Operating Expenses was -$18.8 million (2023), whereas its average is -$19.0 million.
  • As far as peak fluctuations go, BioLineRx's Operating Expenses climbed by 18.96% in 2020, and later fell by 7.64% in 2021.
  • Yearly analysis of 5 years shows BioLineRx's Operating Expenses stood at -$22.1 million in 2020, then declined by 7.64% to -$23.8 million in 2021, then grew by 4.54% to -$22.7 million in 2022, then rose by 17.03% to -$18.8 million in 2023, then grew by 17.84% to -$15.5 million in 2024.